MedTrace Logo

A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

NCT02522650 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-02-07

No results posted yet for this study

Summary

This cross-over study is designed to test the hypothesis that amiloride will reduce urinary protein excretion and protect the kidney from rapid progression in proteinuric kidney disease.

Conditions

  • Proteinuria

Interventions

DRUG

Amiloride

5mg twice a day for 8 weeks

DRUG

Triamterene

50mg twice a day for 8 weeks

Sponsors & Collaborators

  • Georgetown University

    lead OTHER

Principal Investigators

  • Wen Shen, MD, PhD · Georgetown University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02522650 on ClinicalTrials.gov